Are extracellular vesicles a potential treatment for sepsis-related acute lung injury?
Sepsis-related acute lung injury (ALI) is a serious condition with limited treatment options. Extracellular vesicles (EVs) are tiny particles released by cells that can carry signals between cells. Research suggests EVs play a dual role: some EVs may worsen lung injury, while others, especially engineered exosomes, could be used to deliver treatments directly to the lungs. Current evidence is mostly from lab studies and animal models, so it is not yet ready for routine clinical use.
What the research says
One study found that endothelial cell-derived EVs (EC-EVs) increase during sepsis and can worsen lung injury by reprogramming monocytes toward a proinflammatory state 9. These EVs carry a surface protein called VCAM1, which interacts with monocytes to activate the NF-κB pathway, promoting inflammation 9. Blocking VCAM1 or its receptor reduced this effect in lab experiments 9.
On the therapeutic side, a 2025 study showed that exosomes (a type of EV) loaded with a microRNA called miR-23b-3p can be modified with mannose to target alveolar macrophages in the lungs 11. Delivering these exosomes intratracheally in mice alleviated ALI by inhibiting M1 macrophage activation through the Lpar1-NF-κB pathway 11. This approach reduced inflammation and improved lung injury 11.
A 2025 review also highlights extracellular vesicles as promising players in organ-lung crosstalk during sepsis, suggesting they could be both mediators of injury and potential therapeutic targets 10. However, the review notes that translating these findings to clinical practice remains challenging due to the complexity of multi-organ interactions 10.
Other sources in the provided set do not directly address extracellular vesicles as a treatment for sepsis-related ALI [1-8]. They cover related topics like HMGB1 levels, neutrophil extracellular traps, vitamin D deficiency, and prediction models, but none discuss EV-based therapy.
What to ask your doctor
- Are there any clinical trials testing extracellular vesicle therapies for sepsis-related lung injury?
- What is the current standard treatment for sepsis-related acute lung injury?
- Could my condition benefit from experimental therapies targeting inflammation pathways like NF-κB?
- How do doctors currently monitor lung injury in sepsis patients?
- Are there any risks or side effects associated with extracellular vesicle treatments in early studies?
This question is drawn from common patient questions about Pulmonology & Critical Care and answered using cited medical research. We do not provide individualized advice.